[1. Vögtle T, Cherpokova D, Bender M, Nieswandt B. Targeting platelet receptors in thrombotic and thrombo-inflammatory disorders. Hamostaseologie. 2015;35 [Epub ahead of print]10.5482/HAMO-14-10-004925634564]Search in Google Scholar
[2. Floyd CN, Ferro A. Anti-platelet drug resistance: Molecular insights and clinical implications. Prostaglandins Other Lipid Mediat. 2015; [Epub ahead of print]10.1016/j.prostaglandins.2015.03.01125868910]Search in Google Scholar
[3. Vlachojannis GJ, Dimitropoulos G, Alexopoulos D. Clopidogrel resistance: current aspects and future directions. Hell J Cardiol. 2011;52:236-45.]Search in Google Scholar
[4. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ ACC Guideline for the Management of Patients With Non- ST-Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2014;64:e139-228.10.1016/j.jacc.2014.09.01725260718]Search in Google Scholar
[5. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-619.10.1093/eurheartj/ehs21522922416]Search in Google Scholar
[6. Pyrgakis VN, Goudevenos JA. Clopidogrel and cardiovascular diseases: recommendations for its correct use. Hell J Cardiol. 2010;51:83-6.]Search in Google Scholar
[7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-16.10.1016/j.jacc.2006.11.04417418288]Search in Google Scholar
[8. Papathanasiou A, Goudevenos J TAD. Resistance to Aspirin and Clopidogrel: Possible Mechanisms, Laboratory Investigation, and Clinical Significance. Hell J Cardiol. 2007;48:352-63.]Search in Google Scholar
[9. Dupont AG, Gabriel DA, Cohen MG. Anti-platelet therapies and the role of anti-platelet resistance in acute coronary syndrome. Thromb Res. 2009;124:6-13.10.1016/j.thromres.2009.01.01419324398]Search in Google Scholar
[10. Abacı O, Kılıçkesmez KO. Aspirin resistance: Where are we now? Anadolu Kardiyol Derg. 2013;13:370-3.]Search in Google Scholar
[11. Karaźniewicz-Łada M, Danielak D, Główka F. Genetic and nongenetic factors affecting the response to clopidogrel therapy. Expert Opin Pharmacother. 2012;13:663-83.10.1517/14656566.2012.66652422397459]Search in Google Scholar
[12. Abbate R, Crea F, De Servi S, et al. [Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel]. G Ital Cardiol. 2010;11:127-37.]Search in Google Scholar
[13. Fileti L, Campo G, Valgimigli M. Latest clinical data on testing for high on-treatment platelet reactivity. Rev Cardiovasc Med. 2011;12(Suppl 1):S14-22.10.3909/ricm12S1S0001]Search in Google Scholar
[14. Saraf S, Bensalha I, Gorog DA. Anti-platelet Resistance - Does it Exist and How to Measure it ? Clin Med Cardiol. 2009;3:77-91.]Search in Google Scholar
[15. Ahluwalia K, Bhanwra S. Anti-platelet therapy: present status and its future directions. Int J Basic Clin Pharmacol. 2014;3:260.10.5455/2319-2003.ijbcp20140402]Search in Google Scholar
[16. Patrono C, Coller B, FitzGerald G A., Hirsh J, Roth G. Plateletactive drugs: The relationships among dose, effectiveness, and side effects - The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Supl).10.1378/chest.126.3_suppl.234S15383474]Search in Google Scholar
[17. Bagoly Z, Sarkady F, Magyar T, et al. Comparison of a New P2Y12 Receptor Specific Platelet Aggregation Test with Other Laboratory Methods in Stroke Patients on Clopidogrel Monotherapy. PLoS One. 2013;8:1-11.10.1371/journal.pone.0069417]Search in Google Scholar
[18. Huang B, Huang Y, Li Y, et al. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res. 2012;43:212-24.10.1016/j.arcmed.2012.04.004]Search in Google Scholar
[19. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-33.10.1016/j.jacc.2010.04.047]Search in Google Scholar
[20. Mallouk N, Labruyère C, Reny J-L, et al. Prevalence of poor biological response to clopidogrel: a systematic review. Thromb Haemost. 2012;107:494-506.10.1160/TH11-03-0202]Search in Google Scholar
[21. Aradi D, Komócsi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. 2010;160:543-51.10.1016/j.ahj.2010.06.004]Search in Google Scholar
[22. Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:923-33.10.1111/j.1538-7836.2010.03809.x]Search in Google Scholar
[23. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: An updated meta-analysis. Thromb Haemost. 2010;103:841-8.]Search in Google Scholar
[24. Brar SS, Ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58:1945-54.10.1016/j.jacc.2011.06.059]Search in Google Scholar
[25. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367:606-17.10.1016/S0140-6736(06)68040-9]Search in Google Scholar
[26. Topçuoglu MA, Arsava EM, Ay H. Anti-platelet resistance in stroke. Expert Rev Neurother. 2011;11:251-63.10.1586/ern.10.203308667321306212]Search in Google Scholar
[27. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med. 2008;6:46.10.1186/1479-5876-6-46253850118759978]Search in Google Scholar
[28. Serebruany V, Cherala G, Williams C, et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of “resistance”. Am Heart J. 2009;158:925-32.10.1016/j.ahj.2009.10.012]Search in Google Scholar
[29. Herlitz J, Tóth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10:125-41.10.2165/11318440-000000000-00000]Search in Google Scholar
[30. Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127:377-85.10.1161/CIRCULATIONAHA.112.117283]Search in Google Scholar
[31. Feher G, Feher A, Pusch G, et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol. 2010;2:171-86.10.4330/wjc.v2.i7.171]Search in Google Scholar
[32. Mansour K, Taher AT, Musallam KM, Alam S. Aspirin resistance. Adv Hematol. 2009;2009:1-10.10.1155/2009/937352]Search in Google Scholar
[33. Scott SA, Owusu Obeng A, Hulot J-S. Anti-platelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10:175-89.10.1517/17425255.2014.856883]Search in Google Scholar
[34. Johnson DA, Chilton R, Liker HR. Proton-pump inhibitors in patients requiring anti-platelet therapy: new FDA labeling. Postgrad Med. 2014;126:239-45.10.3810/pgm.2014.05.2772]Search in Google Scholar
[35. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-8.10.1503/cmaj.082001]Search in Google Scholar
[36. Stockl KM. Risk of Rehospitalization for Patients Using Clopidogrel With a Proton Pump Inhibitor. Arch Intern Med. 2010;170:704.10.1001/archinternmed.2010.34]Search in Google Scholar
[37. Neubauer H, Günesdogan B, Hanefeld C, Spiecker M, Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - A flow cytometry study. Eur Heart J. 2003;24:1744-9.10.1016/S0195-668X(03)00442-1]Search in Google Scholar
[38. Park Y, Jeong Y-H, Tantry US, et al. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur Heart J. 2012;33:2151-62.10.1093/eurheartj/ehs08322507978]Search in Google Scholar
[39. Pelliccia F, Rosano G, Marazzi G, et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual anti-platelet therapy. Circ J. 2014;78:679-84.10.1253/circj.CJ-13-1216]Search in Google Scholar
[40. Hedegaard SS, Hvas A-M, Grove EL, et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res. 2009;124:96-100.10.1016/j.thromres.2008.12.03419215971]Search in Google Scholar
[41. Ojeifo O, Wiviott SD, Antman EM, et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio. JACC Cardiovasc Interv. 2013;6:1275-81.10.1016/j.jcin.2013.06.01424239201]Search in Google Scholar
[42. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000;55:843-52.10.1007/s00228005070610805063]Search in Google Scholar
[43. Seo K-D, Kim YD, Yoon Y-W, Kim J-Y, Lee K-Y. Anti-platelet effect of clopidogrel can be reduced by calcium-channel blockers. Yonsei Med J. 2014;55:683-8.10.3349/ymj.2014.55.3.683399009824719135]Search in Google Scholar
[44. Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. The genetics of anti-platelet drug resistance. Clin Genet. 2009;75:1-18.10.1111/j.1399-0004.2008.01105.x19067731]Search in Google Scholar
[45. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: A comprehensive systematic review. Br J Clin Pharmacol. 2008;66: 222-32.10.1111/j.1365-2125.2008.03183.x249291318429969]Search in Google Scholar
[46. Altman R, Flockhart D, Goldstein D. Principles of pharmacogenetics and pharmacogenomics. 1st ed. 2012;121-4.10.1017/CBO9781139051194]Search in Google Scholar
[47. Negovan A, Voidăzan S, Pantea M, et al. AGT A-20C (rs5050) gene polymorphism and ulcer occurrence in patients treated with low-dose aspirin: a case-control study. Rev Romana Med Lab. 2015;23:179-87.]Search in Google Scholar
[48. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-9.10.1124/dmd.109.02913219812348]Search in Google Scholar
[49. Kim KA, Park PW, Hong SJ, Park J-Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84:236-42.10.1038/clpt.2008.2018323861]Search in Google Scholar
[50. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 Polymorphisms and Response to Clopidogrel. N Engl J Med. 2009;360:354-62.10.1056/NEJMoa080917119106084]Search in Google Scholar
[51. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirintreated patients with coronary artery disease. Eur Heart J. 2009;30:1744-52.10.1093/eurheartj/ehp157270988519429918]Search in Google Scholar
[52. Simon T, Céline V, Murielle M-K, et al. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. N Engl J Med. 2009;360:363-75.10.1056/NEJMoa080822719106083]Search in Google Scholar
[53. Seip RL, Duconge J, Ruaño G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 2010;6:409-24.10.2217/fca.10.6290322920462345]Search in Google Scholar
[54. Militaru FC, Vesa ŞC, Crişan S, Militaru V, Trifa AP, Buzoianu AD. Genotype-phenotype correlations in patients treated with acenocoumarol. Rev Romana Med Lab. 2014;22:347-54.]Search in Google Scholar
[55. Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis. 2009;43:119-28.10.1016/j.bcmd.2009.01.019278974119297219]Search in Google Scholar
[56. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Haemostasis. 2005;3:1309-11.10.1111/j.1538-7836.2005.01351.x15892858]Search in Google Scholar
[57. Gasparyan AY, Watson T, Lip GYH. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51:1829-43.10.1016/j.jacc.2007.11.08018466797]Search in Google Scholar
[58. Nguyen NQ, Chapman MJ, Fraser RJ, et al. The effects of sedation on gastric emptying and intra-gastric meal distribution in critical illness. Intensive Care Med. 2008;34:454-60.10.1007/s00134-007-0942-218060542]Search in Google Scholar
[59. Hong J-Y, Oh JI. Effects of preoperative anxiety on gastric fluid acidity and volume. J Korean Med Sci. 2005; 20:232-5.10.3346/jkms.2005.20.2.232280859815831993]Search in Google Scholar
[60. Roush J a. The role of the stomach in drug absorption as observed via absorption rate analysis. Int J Pharm. 2014;471:112-7.10.1016/j.ijpharm.2014.05.01824853462]Search in Google Scholar
[61. Ganesan S, Williams C, Maslen CL, Cherala G. Clopidogrel variability: role of plasma protein binding alterations. Br J Clin Pharmacol. 2013;75:1468-77.10.1111/bcp.12017369010523116430]Search in Google Scholar
[62. Storm C, Schefold JC, Kerner T, et al. Prehospital cooling with hypothermia caps (PreCoCa): A feasibility study. Clin Res Cardiol. 2008;97:768-72.10.1007/s00392-008-0678-118512093]Search in Google Scholar
[63. Bjelland TW, Hjertner Ø, Klepstad P, Kaisen K, Dale O, Haugen BO. Anti-platelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2010;81:1627-31.10.1016/j.resuscitation.2010.07.00220727659]Search in Google Scholar
[64. Součková L, Opatřilová R, Suk P, et al. Impaired bioavailability and anti-platelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013;69:309-17.10.1007/s00228-012-1360-022890586]Search in Google Scholar
[65. Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent). 2000;13:421-3.]Search in Google Scholar
[66. Pascoe MC, Howells DW, Crewther DP, et al. Fish oil diet associated with acute reperfusion related hemorrhage, and with reduced stroke-related sickness behaviors and motor impairment. Front Neurol. 2014;5:14.10.3389/fneur.2014.00014391523924567728]Search in Google Scholar
[67. Wachira JK, Larson MK, Harris WS. n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br J Nutr. 2014;111:1652-62.10.1017/S000711451300425X24472372]Search in Google Scholar
[68. Bradnam V, White R. Handbook of Drug Administration Via Enteral Feeding Tubes, 3rd edition, London, UK: Pharmaceutical Press; 2015.]Search in Google Scholar
[69. Powers JE, Cascella PJ. Comparison of methods used to prepare tablets for nasogastric tube administration. J Pharm Technol. 1990;6:60-2.10.1177/875512259000600209]Search in Google Scholar
[70. Patel V, Kukadiya H, Mashru R, Surti N, Mandal S. Development of microemulsion for solubility enhancement of clopidogrel. Iran J Pharm Res IJPR. 2010;9:327-34.]Search in Google Scholar
[71. Lenk E, Spannagl M. Platelet function testing - guided antiplatelet therapy. J Int Fed Clin Chem Lab Med. 2013;24:1-7.]Search in Google Scholar
[72. Breet NJ, Werkum JW van, Bouman HJ, et al. Comparison of Platelet Function Tests Undergoing Coronary Stent Implantation. JAMA. 2010;303:754-62.10.1001/jama.2010.18120179285]Search in Google Scholar
[73. Paniccia R. Assessment of platelet function: Laboratory and point-of-care methods. World J Transl Med. 2014;3:69.10.5528/wjtm.v3.i2.69]Search in Google Scholar
[74. Gladding P, Webster M, Ormiston J, Olsen S, White H. Antiplatelet drug nonresponsiveness. Am Heart J. 2008;155:591-9.10.1016/j.ahj.2007.12.03418371464]Search in Google Scholar
[75. Tousoulis D, Siasos G, Stefanadis C. Aspirin resistance: what the cardiologist needs to know? Int J Cardiol. 2009;132:153-6.]Search in Google Scholar
[76. Michelson AD. Platelets. 2nd ed. 2007;545-63.10.1016/B978-012369367-9/50792-8]Search in Google Scholar
[77. Gachet C, Aleil B. Testing anti-platelet therapy. Eur Hear J Suppl. 2008;10(Suppl A):A28-34.10.1093/eurheartj/sum081]Search in Google Scholar
[78. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol. 2005;130:3-10.10.1111/j.1365-2141.2005.05511.x15982339]Search in Google Scholar
[79. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4:312-9.10.1111/j.1538-7836.2006.01771.x16420557]Search in Google Scholar
[80. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost. 2008;34:709-33.10.1055/s-0029-114525419214910]Search in Google Scholar
[81. Hussein HM, Emiru T, Georgiadis AL, Qureshi AI. Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures. Am J Neuroradiol. 2013;34:700-6.10.3174/ajnr.A2963796447622422188]Search in Google Scholar
[82. Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35:209-15.10.1093/eurheartj/eht375389686124067509]Search in Google Scholar
[83. Meybohm P, Zacharowski K, Weber CF. Point-of-care coagulation management in intensive care medicine. Crit Care. 2013;17:218.10.1186/cc12527367263423510484]Search in Google Scholar
[84. Adamzik M, Gorlinger K, Peters J, Hartmann M. Whole blood impedance aggregometry as a biomarker for the diagnosis and prognosis of severe sepsis. Crit Care. 2012;16:R204.10.1186/cc11816368230723088388]Search in Google Scholar
[85. Short S, Kram B, Taylor S, Cheng J, Ali K, Vasquez D. Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel. J Trauma Acute Care Surg. 2013;74:1419-24.10.1097/TA.0b013e31828dac3e23694867]Search in Google Scholar
[86. Clareus A, Fredriksson I, Wallén H, Gordon M, Stark A, Sköldenberg O. Variability of platelet aggregation in patients with clopidogrel treatment and hip fracture: A retrospective case-control study on 112 patients. World J Orthop. 2015;6:439-45.10.5312/wjo.v6.i5.439445849526085986]Search in Google Scholar
[87. Rosengart TK, Romeiser JL, White LJ, et al. Platelet activity measured by a rapid turnaround assay identifies coronary artery bypass grafting patients at increased risk for bleeding and transfusion complications after clopidogrel administration. J Thorac Cardiovasc Surg. 2013;146:1259-66, 1266.e1; discussion 1266.]Search in Google Scholar
[88. Mishra P, Thekkudan J, Sahajanandan R, et al. The role of point-of-care assessment of platelet function in predicting postoperative bleeding and transfusion requirements after coronary artery bypass grafting. Ann Card Anaesth. 2015;18:45.10.4103/0971-9784.148321490032725566711]Search in Google Scholar
[89. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:849-56. 10.1016/j.jacc.2008.11.03019264241]Search in Google Scholar